Association of Tumor Necrosis Factor-Alpha (TNF-α) With Hepatitis C Virus Infection: A Case-Control Study
Keywords:
Hepatitis C Virus, Tnf- Α, ELISA, BMIAbstract
Background: Although apparent antiviral medications have greatly increased the likelihood of eradication, hepatitis C virus (HCV) infection is still a major host threat to liver infection and disease development because chronic contamination can result in persistent liver insufficiency, fibrosis, cirrhosis, and hepatocellular carcinoma. One important perceived inflammatory cytokine implicated in innate adaptive immune responses and chronic HCV is tumour necrosis factor-alpha (TNF-α). The purpose of this study was to assess the possible status of TNF-α as a marker of the pro-inflammatory immune response linked to HCV infection and to compare serum TNF-α concentrations in patients with HCV infection with those of seemingly healthy controls.
Materials and Methods: A quantitative sandwich enzyme-linked immunosorbent assay (ELISA) was used to assess blood TNF-α concentrations in a case-management study of 80 volunteers, comprising 40 patients with HCV infection and 40 trustworthy healthy controls. Anthropometric and demographic traits have also been evaluated.
Results: Compared to healthy controls, individuals with HCV had substantially higher serum TNF-α values. The HCV group's adjusted serum TNF-α consciousness was 59.14 ± 31.27 pg/mL, whereas the management populations was 18.15 ± 6,81 pg/mL. It was shown that differences between businesses were statistically significant (P < 0.001). In conclusion, a substantial increase in serum TNF-α was shown to be correlated with HCV infection. TNF-α may also have potential as an immune marker of HCV contamination inflammation because elevated TNF-α awareness may also reflect more desirable pro-inflammatory immune activation in HCV-infected subjects and contribute to the inflammatory environment associated with liver injury. However, large-scale studies involving viral load, liver biochemical index, fibrous phase.
References
World Health Organization. (2026). Consolidated guidelines on hepatitis B and C prevention, testing, treatment, service delivery and monitoring: An implementation handbook for a public health approach. World Health Organization.
Lumnitzer, M. E. (2026). The Transcription Factor AFF3 Maintains Naïve CD8 T Cell Quiescence Allowing for a Robust Immune Response to Viral Infection (Doctoral dissertation, Indiana University Indianapolis).
Apol, Á. D., Sølund, C., Vinten, C., Underwood, A. P., Bukh, J., & Weis, N. (2025). Cure of chronic hepatitis C virus infection after DAA treatment only partially restores the functional capacity of exhausted T cell subsets: A systematic review. Frontiers in Immunology, 16, 1546915.
Wallace, H. L., & Russell, R. S. (2024). Inflammatory consequences: Hepatitis C virus-induced inflammasome activation and pyroptosis. Viral immunology, 37(3), 126-138.
Yi, Q., Yang, J., Wu, Y., Wang, Y., Cao, Q., & Wen, W. (2023). Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells. Frontiers in immunology, 14, 1204524.
Sedger, L. M., & McDermott, M. F. (2014). TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants—past, present and future. Cytokine & Growth Factor Reviews, 25(4), 453–472. https://doi.org/10.1016/j.cytogfr.2014.07.016
Petrizzo, A. (2012). Multiparametric analysis of immune-therapeutic model for HCV associated B cell non-Hodgkin’s lymphoma.
Kamboj, S., & Kumar, M. (2025). Integrated transcriptomic analyses identifies host-targeting repurposing drugs for hepatitis C virus infection and related hepatocellular carcinoma. bioRxiv, 2025-05.
Friedman, S. L. (2003). Liver fibrosis–from bench to bedside. Journal of hepatology, 38, 38-53.
Nelson, D. R., Lim, H. L., Marousis, C. G., Fang, J. W., Davis, G. L., Shen, L., Urdea, M. S., Kolberg, J. A., & Lau, J. Y. (1997). Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Digestive Diseases and Sciences, 42(12), 2487–2494. https://doi.org/10.1023/A:1018804426724
Ren, Y., Duan, Z. H., Meng, Q. H., Li, Z., & Li, J. (2009). Relationship between the level of serum TNF-alpha of patients with chronic hepatitis C and treatment with interferon-alpha and the influencing factors. Zhonghua shi yan he lin Chuang Bing du xue za zhi= Zhonghua Shiyan he Linchuang Bingduxue Zazhi= Chinese Journal of Experimental and Clinical Virology, 23(2), 129-131.
Arzumanyan, A., Reis, H. M., & Feitelson, M. A. (2013). Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nature Reviews Cancer, 13(2), 123-135.
Aroucha, D. C., Carmo, R. F., Vasconcelos, L. R. S., Lima, R. E., Mendonça, T. F., Arnez, L. E., ... & Coêlho, M. R. (2016). TNF‐α and IL‐10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals. Journal of medical virology, 88(9), 1587-1595.
Ferreira, J., Caldeira, J., Bicho, M., Faustino, P., & Serejo, F. (2026). Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation, Inflammatory–Oxidative Pathogenesis and Epigenetic Memory. International Journal of Molecular Sciences, 27(8), 3559.
Hearps, A. C., Vootukuru, N., Ebrahimnezhaddarzi, S., Harney, B. L., Boo, I., Nguyen, L., ... & Doyle, J. S. (2024). Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy. Frontiers in immunology, 15, 1352440.
Lu, M. Y., Yeh, M. L., Huang, C. I., Wang, S. C., Tsai, Y. S., Tsai, P. C., ... & Yu, M. L. (2022). Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World Journal of Gastroenterology, 28(1), 140.
Arias-Loste, M. T., Cabezas, J., Llerena, S., Iruzubieta, P., San-Segundo, D., Merino, D., ... & Crespo, J. (2021). Successful Direct Acting Antiviral Therapy in Chronic Hepatitis C Normalizes IFNγ and IL2 Production in T Cells Together with TLR8 Expression and Functionality in Peripheral Blood Mononuclear Cells. Viruses, 13(4), 635.
Farcomeni, S., Moretti, S., Fimiani, C., Sulekova, L. F., Vescio, F., Sernicola, L., ... & Borsetti, A. (2021). Short-and long-term immunological responses in chronic HCV/HIV co-infected compared to HCV mono-infected patients after DAA therapy. Pathogens, 10(11), 1488.
Medeiros, T., Saraiva, G. N., Moraes, L. A., Gomes, A. C., Lacerda, G. S., Leite, P. E., ... & Silva, A. A. (2020). Liver fibrosis improvement in chronic hepatitis C after direct acting-antivirals is accompanied by reduced profibrogenic biomarkers–a role for MMP-9/TIMP-1. Digestive and Liver Disease, 52(10), 1170-1177.
Cheng, C. H., Chu, C. Y., Chen, H. L., Lin, I. T., Wu, C. H., Lee, Y. K., ... & Bair, M. J. (2021). Direct-acting antiviral therapy of chronic hepatitis C improves liver fibrosis, assessed by histological examination and laboratory markers. Journal of the Formosan Medical Association, 120(5), 1259-1268.
Tanwar, S., Rhodes, F., Srivastava, A., Trembling, P. M., & Rosenberg, W. M. (2020). Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World journal of gastroenterology, 26(2), 109.
Saltiel, A. R., & Olefsky, J. M. (2017). Inflammatory mechanisms linking obesity and metabolic disease. The Journal of clinical investigation, 127(1), 1-4.
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology, 14(10), 576-590.
